Clinical findings shed more light on toxins produced by C. diff A team from Nashville, Tenn.-based VanderbiltUniversityMedicalCenter has teased out new secrets from Clostridium difficile, the ...

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the ...

Fecal microbiota transplantation has become one of the most effective treatments for recurrent Clostridioides difficile infections, but its long-term role in gastroenterology may hinge on moving ...

The presence of antigen-specific and neutralizing antibodies was not associated with Clostridioides difficile infection symptoms, severity, therapy approach, treatment response, or recurrences in a ...

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the ...

Isolating asymptomatic C. diff carriers linked with lower incidence of infection Screening and isolating asymptomatic Clostridium difficile carriers was associated with a reduction in incidence of ...

The bacterium commonly referred to as C. diff is sometimes called “C-difficult” because it is so hard to treat, said Mohamed Seleem, director of the Center for One Health Research. Seleem and Nectagen ...

The bacterium Clostridioides difficile, which was formerly named Clostridium difficile and is now commonly known as C. difficile or simply C. diff, is a common microorganism found in the environment.

The study of Clostridium difficile infection (CDI) continues to reveal intricate details of its pathogenesis, epidemiology and potential novel therapies. Research has elucidated how the bacterium, ...

On the left is an illustration of the deadly C. diff bacteria as seen under a microscope. The image on the right, resembling a question mark, is the first three-dimensional crystal structure of TcdB ...